21 Jul 2025 A systematic review of tofacitinib in the treatment of adult patients with psoriatic arthritis
This report is a systematic review of tofacitinib for the treatment of adult patients with psoriatic arthritis. Tofacitinib is a Janus kinase inhibitor (JAKi), a type of anti-inflammatory rheumatic drug. It blocks the activity of Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2) involved in the JAK-STAT pathway of inflammation and immune response.
The research question that this report answers is: in double-blind randomized controlled trials, does tofacitinib provide a therapeutic advantage compared to placebo or active comparators in the treatment of adult patients with psoriatic arthritis?
Click on the ‘Download‘ button to view or download the report (PDF format).
No Comments